of prednisone or nonfluorinated equivalent) during pregnancy if clinically indicated. We strongly recommend tapering higher doses of nonfluorinated glucocorticoids to <20 mg daily of prednisone, adding a pregnancy-compatible glucocorticoid-sparing agent if necessary. Although there are only minimal data regarding prolonged treatment with low-dose glucocorticoids during pregnancy, we conditionally recommend against routine administration of stress-dose glucocorticoids at the time of vaginal